Inuzuka T, Sato S, Baba H, Miyatake T
Acta Neurol Scand. 1987 Jul;76(1):18-23. doi: 10.1111/j.1600-0404.1987.tb03538.x.
Neutral protease activity was significantly elevated in the cerebro-spinal fluid of patients with multiple sclerosis (MS) in exacerbation and in the acute phase of acute viral meningoencephalitis (AME) compared with that of MS in remission, amyotrophic lateral sclerosis or psychosomatic disease. Since in each relapse of MS, protease activity was higher in exacerbation than in remission, this activity may be one good marker of disease activity in MS. One hundred micro molar of FOY305, synthetic protease inhibitor, inhibited in vitro increased neutral protease activity in MS in exacerbation, which suggests the possibility of a clinical application of this protease inhibitor for MS.
与缓解期的多发性硬化症(MS)、肌萎缩侧索硬化症或心身疾病患者相比,复发期多发性硬化症(MS)患者以及急性病毒性脑膜脑炎(AME)急性期患者脑脊液中的中性蛋白酶活性显著升高。由于MS每次复发时,复发期的蛋白酶活性均高于缓解期,因此该活性可能是MS疾病活动的一个良好标志物。100微摩尔的合成蛋白酶抑制剂FOY305可在体外抑制复发期MS患者中性蛋白酶活性的升高,这表明该蛋白酶抑制剂有可能用于MS的临床治疗。